TR200003281T2 - CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları. - Google Patents

CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.

Info

Publication number
TR200003281T2
TR200003281T2 TR2000/03281T TR200003281T TR200003281T2 TR 200003281 T2 TR200003281 T2 TR 200003281T2 TR 2000/03281 T TR2000/03281 T TR 2000/03281T TR 200003281 T TR200003281 T TR 200003281T TR 200003281 T2 TR200003281 T2 TR 200003281T2
Authority
TR
Turkey
Prior art keywords
antibodies
derivatives
therapeutic uses
rii
bind
Prior art date
Application number
TR2000/03281T
Other languages
English (en)
Inventor
Marcel Paul Bonnefoy Jean-Yves
James Crowe Scott
Henry Ellis Jonathan
Timothy Rapson Nicholas
Shearin Jean
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200003281T2 publication Critical patent/TR200003281T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bulus, CD23 (FC RII) tip II molekülüne baglanan antikorlara, özellikle, 1x10 Ka Mo1 den daha büyük ya da esit bir afinite sabiti ile vasiflanan CD23 (FC RII) tip II molekülüne baglanan antikorlari kapsayan degistirilmis antikorlara, bu antikorlarin hazirlanmasi, bu antikorlari ihtiva eden farmasötik bilesimler ve bunlarin terapide, özellikle otoimün ve iltihapli bozukluklarin tedavisinde kullanimlarina iliskindir.
TR2000/03281T 1998-05-09 1999-05-07 CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları. TR200003281T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody

Publications (1)

Publication Number Publication Date
TR200003281T2 true TR200003281T2 (tr) 2001-03-21

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03281T TR200003281T2 (tr) 1998-05-09 1999-05-07 CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.

Country Status (25)

Country Link
US (1) US7008623B1 (tr)
EP (1) EP1076701A1 (tr)
JP (1) JP2002514421A (tr)
KR (1) KR20010043470A (tr)
CN (1) CN1308676A (tr)
AP (1) AP1547A (tr)
AU (1) AU763491B2 (tr)
BR (1) BR9910327A (tr)
CA (1) CA2328606A1 (tr)
EA (1) EA200001041A1 (tr)
EE (1) EE200000658A (tr)
GB (1) GB9809839D0 (tr)
HR (1) HRP20000762A2 (tr)
HU (1) HUP0102005A3 (tr)
ID (1) ID28088A (tr)
IL (1) IL139384A0 (tr)
IS (1) IS5696A (tr)
NO (1) NO20005632L (tr)
NZ (1) NZ507879A (tr)
PL (1) PL344019A1 (tr)
SK (1) SK16762000A3 (tr)
TR (1) TR200003281T2 (tr)
WO (1) WO1999058679A1 (tr)
YU (1) YU69000A (tr)
ZA (1) ZA200006312B (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
JP2004532608A (ja) 2000-10-13 2004-10-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ヒト化抗ＬＴ−β−Ｒ抗体
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CA2434668A1 (en) * 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
EP2135619A1 (en) * 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SI2380592T1 (en) * 2005-11-14 2018-06-29 Teva Pharmaceuticals International Gmbh The antibody to the calcitonin-related peptide antagonist
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
CN101959528A (zh) 2008-03-04 2011-01-26 辉瑞有限公司 治疗慢性疼痛的方法
PE20091882A1 (es) 2008-05-06 2009-12-24 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
CA2753332A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753263A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010122090A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Fgfr1c antibody combinations
EP3165236B1 (en) 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
LT3415531T (lt) 2011-05-27 2023-09-25 Glaxo Group Limited Bcma (cd269/tnfrsf17) – surišantys baltymai
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
EP3019525B1 (en) * 2013-07-10 2019-04-17 Onconox ApS Antibodies to beta2-glycoprotein i and therapeutic uses thereof
PE20220337A1 (es) 2014-03-21 2022-03-14 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ES2842306T3 (es) 2015-09-02 2021-07-13 Immutep Sas Anticuerpos anti LAG-3
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
US10479827B2 (en) 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266965B1 (en) * 1991-07-25 2006-05-24 Biogen Idec Inc. Recombinant antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
KR20040058016A (ko) * 1994-10-25 2004-07-02 글락소 그룹 리미티드 Ｃｄ23에 대한 결합제
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
PL344019A1 (en) 2001-09-24
NZ507879A (en) 2004-02-27
WO1999058679A1 (en) 1999-11-18
HRP20000762A2 (en) 2001-06-30
AP2000001983A0 (en) 2000-12-31
NO20005632D0 (no) 2000-11-08
HUP0102005A3 (en) 2003-10-28
CN1308676A (zh) 2001-08-15
KR20010043470A (ko) 2001-05-25
GB9809839D0 (en) 1998-07-08
IL139384A0 (en) 2001-11-25
IS5696A (is) 2000-10-31
EA200001041A1 (ru) 2001-06-25
BR9910327A (pt) 2001-01-30
SK16762000A3 (sk) 2001-07-10
AU763491B2 (en) 2003-07-24
EP1076701A1 (en) 2001-02-21
AP1547A (en) 2006-01-13
YU69000A (sh) 2003-08-29
CA2328606A1 (en) 1999-11-18
JP2002514421A (ja) 2002-05-21
AU3836799A (en) 1999-11-29
HUP0102005A2 (hu) 2001-10-28
NO20005632L (no) 2001-01-08
ID28088A (id) 2001-05-03
ZA200006312B (en) 2003-02-26
EE200000658A (et) 2002-04-15
US7008623B1 (en) 2006-03-07

Similar Documents

Publication Publication Date Title
TR200003281T2 (tr) CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
ATE427353T1 (de) Heregulin varianten
DE69637781D1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
DK0910647T3 (da) Human DNase i hyperaktive varianter
TR199902562T2 (tr) Degistirilmis TNF alfa molekülleri
DE69432412T2 (de) Gelonin und einen antikörper entahltende immuntoxine
DK0839143T3 (da) Tetralinforbindelser med MDR-aktivitet
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
BR9910860A (pt) Uso de ciclosporinas no tratamento de doenças auto-imunes inflamatórias
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
DE69612056T2 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE278017T1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
BRPI0414174A (pt) moléculas de ligação nogo-a e o uso farmacêutico das mesmas
TR199902866T2 (tr) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlari, hazirlanmalari ve terapide kullanilmalari için prosesler.
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
NO973876L (no) Human-DNase I-varianter
TR199700842T1 (tr) Insan DNase I Varyantlari.
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
MX9706429A (es) Variantes de dnasa i humana.